

“food which is formulated to be consumed or administered enterally under the supervision of a physician and which is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation.”

This technology discloses formulation and methods of using novel stealth lipid nanoparticles that have a high stability and payload capacity. Combination of these nanoparticles with selected agents may have various medical applications for cancer and anti-inflammatory indications.

This notice is made in accordance with 35 U.S.C. 209 and 37 CFR 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the National Cancer Institute receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.

In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available.

License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information from these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552.

Dated: April 16, 2021.

Richard U. Rodriguez,

Associate Director, Technology Transfer Center, National Cancer Institute.

[FR Doc. 2021-09332 Filed 5-3-21; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed).

Date: May 26, 2021.

Time: 10:00 a.m. to 2:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G41, Rockville, MD 20892 (Virtual Meeting).

Contact Person: Tara Capece, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G41, Rockville, MD 20852, 240-191-4281, capecet2@niaid.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: April 28, 2021.

Tyeshia M. Roberson,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2021-09270 Filed 5-3-21; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of an Exclusive Patent License: Development and Commercialization of Cell Therapies for Cancer

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Athenex, Inc. (“Athenex”) headquartered in Buffalo, NY.

DATES: Only written comments and/or applications for a license which are

received by the National Cancer Institute’s Technology Transfer Center on or before May 19, 2021 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, and comments relating to the contemplated an Exclusive Patent License should be directed to: Suna Gulay French, Ph.D., Technology Transfer Manager, NCI Technology Transfer Center, Telephone: (240) 276-5530; Email: suna.gulay@nih.gov.

SUPPLEMENTARY INFORMATION:

Intellectual Property

Group A

E-237-2017-0/2: T Cell Receptors Recognizing Mutated P53

1. US Provisional Patent Application 62/565,383, filed September 29, 2017 (E-237-2017-0-US-01);
2. International Patent Application PCT/US2018/051285, filed September 17, 2018 (E-237-2017-2-PCT-01);
3. Australian Patent Application 2018342246, filed September 17, 2018 (E-237-2017-2-AU-02);
4. Brazilian Patent Application BR112020006012-7, filed September 17, 2018 (E-237-2017-2-BR-03);
5. Canadian Patent Application 3077024, filed September 17, 2018 (E-237-2017-2-CA-04);
6. Chinese Patent Application 201880074539.8, filed September 17, 2018 (E-237-2017-2-CN-05);
7. Costa Rica Patent Application 2020-0170, filed September 17, 2018 (E-237-2017-2-CR-06);
8. Eurasian Patent Application 202090757, filed September 17, 2018 (E-237-2017-2-EA-07);
9. European Patent Application 18780006.5, filed September 17, 2018 (E-237-2017-2-EP-08);
10. Israeli Patent Application 273515, filed September 17, 2018 (E-237-2017-2-IL-09);
11. India Patent Application 202047013911, filed September 17, 2018 (E-237-2017-2-IN-10);
12. Japanese Patent Application 2020-517556, filed September 17, 2018 (E-237-2017-2-JP-11);
13. Korean Patent Application 2020-7012344, filed September 17, 2018 (E-237-2017-2-KR-12);
14. Mexico Patent Application MX/a/2020/003504, filed September 17, 2018 (E-237-2017-2-MX-13);
15. New Zealand Patent Application 763023, filed September 17, 2018 (E-237-2017-2-NZ-14);
16. Singapore Patent Application 11202002636P, filed September 17, 2018 (E-237-2017-2-SG-15);